$18.40
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Warehouse:


diyucha rechovina: cocarboxylase;


1 tablet to mix tiamin pyrophosphate chloridaminoacetato-magnium (II) potassium salt trihydrate in pererahuvannya for 100 % speech 25 mg abo 50 mg;


dopomizhni rechovini: lactose, monohydrate; cellulose microcrystalline; zukrov powder; calcium stearate.


Likarska form. Pills.


The main physico-chemical power: tablets of a white ring, a round shape with a biconvex surface that is at risk on one side.


Pharmacotherapeutic group.


Simply prepare vitamin B1. ATX code A11D A.


Pharmacologichni vlastovosti.


Pharmacodynamics.


Tiamin pyrophosphate Chloridaminoacetate-magnesium (II) potassium salt trihydrate is an original coordination compound of cocarboxylase (tiamin pyrophosphate hydrochloride). In fact, at the warehouse of the ion magnet, the amino acid glycine is superconducted by the activity of cocarboxylase, the enzyme of the carbohydrate protein, for which it is coenzyme.


In the organism of cocarboxylase in a complex with protein and magnesium ions, a storage particle of carboxylase enzyme, which is catalized by decarboxylation and carboxylation of a-keto acids. Cocarboxylase is activated by the main enzyme of the carbohydrate protein, which is superconducted by the use of glucose-rich tannins. Posilennya glucose metabolism should be reduced to the activation of the tannic dihannya, pydvishchennya producuvannya ATP ta zmenshennya accumulated lactic acid. Vkazaniy vpliv suprovodzhuyetsya pokraschennyam metabolic processes, especially in the case of zukrovym diabeti. Cocarboxylase spree is a powerful utility of pyrovinogradic acid, which superconducts the redness of the function of nerve fibers in case of tsukrovogo diabetes and changes in the appearance of neuropathy.


Cocarboxylase-Forte spria normalizatsii obminu klitin in the minds of ishemii ta hypoxia. Zastosuvannya drug in the camps, pov'yazanyh z activation of the vilnoradikalnyh reactions, superconducting redness of the antioxidant status.


Pharmacokinetics.


For sublingual (pid'azichny) priyom warehouse drug shvidko vsmoktuyatsya at the shelter. The maximum concentration in blood plasma begins after 0.5-1.5 years. Producti metabolizmu vivodyatsya nirkami.


Klinichni characteristics.


Shown.


At the warehouse of the complex likuvannya:


- zukrovogo diabetu ta yogo uskladnen;


- zahvoryuvan pechinki nezalezhno vid etiologii, for the first time the activity of hepatocytes to the most pathological vpliviv (virusnih, zapalnih, intoksikatsiynih);


- pechinkovo drawback;


- ishemichno khvorobi sertsya;


- peripheral neuritis;


- zapalnih ta toxic urazhen sertsevogo m'yaza (miocarditiv);


- myocardiopathy.


Protipokazannya.


The sensitivity to the drug is improved.


In return for the best likarsky zasobami that inshi vidi in return.


At one-hour zastosuvanni Kokarboxylaziforte z zukroznizhuvalnimi zasobami slid vrahovuvati posilennya activity.


Cocarboxylase posilyu cardiotonic diyu sertsevih glycosidiv i kraschuyeh tolerable.


Especially zastosuvannya.


When we are exposed to the drug Cocarboxylase-Forte, we bet on a zucroviy diabet slid to control the level of glucose in the blood.


When conducting complex therapy, it is necessary to vrahuvati the power of cocarboxylase posiluvati cardiotonic diu sertsevih glycosides.


Patients with iz rydkisnimi decline problems of lactose intolerance, lactase deficiency Lappa abo glucose-galactose malabsorption do not use the drug Cocarboxylase-Astrapharm.


Zastosuvannya u period vagitnosti abo goduvannya gruddyu.


Efektivnist i bezpeka zastosuvannya kokarboxylase gidrokhloridu at the period of vagitnosty abo goduvannya gruddyu not vstanovlenii, the drug is not recommended for this period.


Zdatnist vplivati na shvidkist reaktsii pri keruvannii motor transport abo inshimi mechanizmami.


Not vyvchalasya.


Sposib zastosuvannya ta dozi.


At the skin vipadku sposib ta dozy zastosuvannya drug vstanovlyu likar individualno.


Dorosli ta diti vikom vid 12 rokiv zazvichay tablets priymayut pid yazik, zatrimyuchi u roti to povny rozsmoktuvannya, 3-4 times on the doba. You can also take the drug internally for 10-15 khvilin before implantation, 3-4 times per dose. Trivaliste course likuvannya zazvichay become 20-30 days.


Diti.


Efektivnist ta bezpeka zastosuvannya kokarboxylazi dityam vikom to 12 rokiv not vivchen, that the drug is not recommended to be assigned to the cii vikov category of patients.


Peredozuvannya.


It is possible to show a positive and individual sensitivity to the drug. Peredozuvannya can manifest itself in the eyes of a large number of twisted forms of secondary reactions.


Recommended pripinennya zastosuvannya drug; symptomatically likuvannya, strayamovane on normalizatsiyu dihannya ta diyalnosti sertsevo-sudinnoy system.


Poblichni reaktsii.


On the side of the immune system: there are possible allergic reactions, there are numerous reactions of hyperchutlivost. Symptoms can be variyuvati vid sverbezhu, shkirny visipannya, kropiv’yankees to roswitku anaphylactic shock.


I have a different dose of slid zniziti abo vidminiti drug. Pislya vidmini drug vsi pobichni efekti shvidko znikayut.


Termin appendages.


3 rocky.


Umovi zberigannya.


Zberigati in original packaging at temperatures not higher than +15 °C.


Zberigati u inaccessible to children of the world.


Packaging.


10 tablets at the blisteri; 3 blisteri at the box.


Category of the vidpusku. Without a prescription.


Virobnik.


TOV "Astrapharm".


Mistseznahodzhennya virobnika ta addresses mistsya provadzhennya yogo diyalnosti.


Ukraine, 08132, Kiev region, Kiev-Svyatoshinsky district, M. Vishnev, vul. Kievska, 6.


Virobnik.


TOV "Pharmaceutical company "FarKoS".


Mistseznahodzhennya virobnika ta addresses mistsya provadzhennya yogo diyalnosti.


Ukraine, 08290, Kiev region, m. Irpin,, mst. Gostomel, vul. Svyato-Pokrovska, 360.


MANUAL


on the medical use of the drug


COCARBOXYLASE-FORTE


(COCARBOXYLASE-FORTE)


Composition:


active substance: cocarboxylase;


1 tablet contains thiamine pyrophosphate chloridaminoacetate-magnesium (II) potassium trihydrate salt in terms of 100 % substance 25 mg or 50 mg;


excipients: lactose, monohydrate; microcrystalline cellulose; sugar powder; calcium stearate.


The dosage form. Pills.


Basic physical and chemical properties: tablets are white, round in shape with a biconvex surface and with a risk on one side.


Pharmacotherapeutic group.


Simple preparations of vitamin B1. ATX code A11D A.


Pharmacological properties.


Pharmacodynamics.


Thiamine pyrophosphate Chloridaminoacetate-magnesium (II) potassium salt trihydrate is the original coordination compound of cocarboxylase (thiamine pyrophosphate hydrochloride). The presence of magnesium ions and the amino acid glycine in the compound is accompanied by an increase in the activity of cocarboxylase relative to carbohydrate metabolism enzymes, for which it is a coenzyme.


In the body, cocarboxylase in combination with protein and magnesium ions is a component of the carboxylase enzyme that catalyzes the decarboxylation and carboxylation of a-keto acids. Cocarboxylase activates the main enzymes of carbohydrate metabolism, which is accompanied by increased glucose utilization by tissues. Increased glucose metabolism leads to the activation of tissue respiration, increased production of ATP and a decrease in the accumulation of lactic acid. This effect is accompanied by an improvement in metabolic processes, especially in diabetes mellitus. Cocarboxylase promotes a more complete utilization of pyruvic acid, which is accompanied by an improvement in the function of nerve fibers in diabetes mellitus and a decrease in the phenomena of neuropathy.


Cocarboxylase-Forte contributes to the normalization of cell metabolism in conditions of ischemia and hypoxia. The use of the drug in conditions associated with the activation of free radical reactions is accompanied by an improvement in the antioxidant status.

Pharmacokinetics.


After sublingual (sublingual) administration, the components of the drug are quickly absorbed into the blood. The maximum concentration in the blood plasma is determined after 0.5-1.5 hours. Metabolic products are excreted by the kidneys.


Clinical characteristics.


Indications.


As part of a complex treatment:


- diabetes mellitus and its complications;


- liver diseases, regardless of etiology, to increase the activity of hepatocytes to various pathological influences (viral, inflammatory, intoxication);


- liver failure;


- coronary heart disease;


- peripheral neuritis;


- inflammatory and toxic lesions of the heart muscle (myocarditis);


- myocardiopathy.


Contraindications.


Hypersensitivity to the drug.


Interaction with other drugs and other types of interactions.


With the simultaneous use of Cocarboxylase-Forte with hypoglycemic agents, it is necessary to take into account the increase in their activity.


Cocarboxylase enhances the cardiotonic effect of cardiac glycosides and improves their tolerability.


Features of the application.


When using the drug Cocarboxylase-Forte, patients with diabetes mellitus should monitor the level of glucose in the blood.


When conducting complex therapy, it is necessary to take into account the property of cocarboxylase to enhance the cardiotonic effect of cardiac glycosides.


Patients with rare hereditary problems of lactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not use the drug Cocarboxylase-Astrapharm.


Use during pregnancy or lactation.


The effectiveness and safety of the use of cocarboxylase hydrochloride during pregnancy or lactation have not been established, so it is not recommended to prescribe the drug during this period.


The ability to influence the reaction speed when driving vehicles or other mechanisms.


It was not studied.


Method of administration and dosage.


In each case, the method and dose of the drug is determined by the doctor individually.


Adults and children from 12 years old usually take tablets under the tongue, holding them in the mouth until they are completely absorbed, 3-4 times a day. It is also possible to take the drug orally 10-15 minutes before eating, 3-4 times a day. The duration of the course of treatment is usually 20-30 days.


Children.


The effectiveness and safety of the use of cocarboxylase in children under 12 years of age have not been studied, so the drug is not recommended for this age group of patients.


Overdose.


It is possible to increase the manifestations of increased individual sensitivity to the drug. Overdose can manifest itself in the form of a more pronounced form of adverse reactions.


It is recommended to discontinue the use of the drug; symptomatic treatment aimed at normalizing breathing and the activity of the cardiovascular system.


Adverse reactions.


The drug is well tolerated, side effects develop very rarely. In some cases, people with increased individual sensitivity to the components of the drug may develop allergic reactions (urticaria, skin rashes, itching) when using it. In this case, the dose should be reduced or the drug should be discontinued. After discontinuation of the drug, all side effects quickly disappear.

Tags: Cocarboxylase